Featured Research

from universities, journals, and other organizations

Getting Down To Specifics: Blocking One RANK Function Inhibits Bone Loss

Date:
March 2, 2009
Source:
Journal of Clinical Investigation
Summary:
A new report describes the development of a cell-permeable inhibitor that specifically blocks the contribution of the protein RANK to the formation and function of the cells responsible for breaking down bone. Importantly, this drug protected against bone loss in two mouse models of diseases associated with bone destruction, leading to the suggestion that this approach might be beneficial to individuals with diseases such as osteoporosis.

A new report describes the development of a cell-permeable inhibitor that specifically blocks the contribution of the protein RANK to the formation and function of the cells responsible for breaking down bone.

Importantly, this drug protected against bone loss in two mouse models of diseases associated with bone destruction, leading to the suggestion that this approach might be beneficial to individuals with diseases such as osteoporosis.

Soo Young Lee and colleagues, at Ewha Womans University, Republic of Korea, have developed a cell-permeable inhibitor of the mouse protein RANK (which they termed RRI) that is likely to aid in the development of selective drugs to treat diseases that involve substantial bone loss, for example, osteoporosis, periodontitis, and arthritis.

Central to understanding diseases that involve substantial loss of bone density, and thereby loss of bone strength, is insight into the molecules that regulate the formation and function of the cells that slowly breakdown bone, cells known as osteoclasts.

One molecule known to regulate both these processes is RANK, however, its utility as a target for drugs that prevent bone destruction might to be limited, as it is involved in many other biological functions.

The authors designed RRI to target a region of RANK that they recently found to be specific for the formation of osteoclasts. RRI was found to inhibit in vitro RANKL-induced formation of mouse osteoclasts and in vitro osteoclast-mediated bone destruction. More importantly, it protected against bone loss in two mouse models of diseases associated with bone destruction, leading to the suggestion similar drugs might be beneficial to individuals with diseases that involve bone destruction, such as osteoporosis.


Story Source:

The above story is based on materials provided by Journal of Clinical Investigation. Note: Materials may be edited for content and length.


Journal Reference:

  1. Kim et al. Selective inhibition of RANK blocks osteoclast maturation and function and prevents bone loss in mice. Journal of Clinical Investigation, 2009; DOI: 10.1172/JCI36809

Cite This Page:

Journal of Clinical Investigation. "Getting Down To Specifics: Blocking One RANK Function Inhibits Bone Loss." ScienceDaily. ScienceDaily, 2 March 2009. <www.sciencedaily.com/releases/2009/03/090302183120.htm>.
Journal of Clinical Investigation. (2009, March 2). Getting Down To Specifics: Blocking One RANK Function Inhibits Bone Loss. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/2009/03/090302183120.htm
Journal of Clinical Investigation. "Getting Down To Specifics: Blocking One RANK Function Inhibits Bone Loss." ScienceDaily. www.sciencedaily.com/releases/2009/03/090302183120.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins